Literature DB >> 17666283

Acquired platelet dysfunction.

Yu-Min P Shen1, Eugene P Frenkel.   

Abstract

Acquired platelet dysfunction is encountered frequently in clinical practice. The usual clinical presentation is that of mucosal bleeding, epistaxis, or superficial epidermal bleeds. Often, the dysfunctional platelets are related to a medication or a systemic disorder. Normally, when platelets are exposed to damaged endothelium, they adhere to the exposed basement membrane collagen and change their shape from smooth disks to spheres with pseudopodia. Then, they secrete the contents of their granules, a process referred to as the release reaction. Additional platelets form aggregates on those platelets that have adhered to the vessel wall. As a result, the primary hemostatic plug is formed, and bleeding is arrested. This article reviews the various forms of acquired platelet dysfunction that result in decreased platelet aggregation, adhesion, or secretion.

Entities:  

Mesh:

Year:  2007        PMID: 17666283     DOI: 10.1016/j.hoc.2007.06.001

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  Persistently elevated laboratory markers of thrombosis and fibrinolysis after clinical recovery in malaria points to residual and smouldering cellular damage.

Authors:  Anirban Dasgupta; Sandeep Rai; Amar Das Gupta
Journal:  Indian J Hematol Blood Transfus       Date:  2011-09-10       Impact factor: 0.900

Review 2.  Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon J Stanworth; Carolyn Doree; Sally Hopewell; Marialena Trivella; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-18

Review 3.  A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Gemma L Crighton; Lise J Estcourt; Erica M Wood; Marialena Trivella; Carolyn Doree; Simon Stanworth
Journal:  Cochrane Database Syst Rev       Date:  2015-09-30

4.  Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality.

Authors:  Patrick Malcolm Siegel; Julia Chalupsky; Christoph B Olivier; István Bojti; Jan-Steffen Pooth; Georg Trummer; Christoph Bode; Philipp Diehl
Journal:  J Thromb Thrombolysis       Date:  2021-09-16       Impact factor: 2.300

5.  Drug-induced hematologic syndromes.

Authors:  David M Mintzer; Shira N Billet; Lauren Chmielewski
Journal:  Adv Hematol       Date:  2009-07-07

Review 6.  Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.

Authors:  Lise J Estcourt; Simon Stanworth; Carolyn Doree; Marialena Trivella; Sally Hopewell; Patricia Blanco; Michael F Murphy
Journal:  Cochrane Database Syst Rev       Date:  2015-10-27

7.  Acquired inhibitors: a special case of bleeding in older adults.

Authors:  Richard G Stefanacci
Journal:  Curr Gerontol Geriatr Res       Date:  2012-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.